

## Platform to advance T-cell therapy development, 11/15

**November 2015—Adaptive Biotechnologies announced a publication** in Science Translational Medicine (Howie B., et al. 2015;7[301]:301ra131) on a novel technology for pairing T-cell receptor alpha and beta chain sequences at high throughput. The PairSeq Assay employs a proprietary process that combines Adaptive's ImmunoSeq Platform for sequencing each TCR chain independently with a bioinformatics framework to facilitate pairing of these chains. The PairSeq Assay enables accurate, rapid, and scalable pairing of up to hundreds of thousands of TCR alpha or beta sequences in a single experiment and can be applied to the process of therapeutic discovery, including the identification of promising TCRs for adoptive T-cell therapy.

[Adaptive Biotechnologies](#), 206-659-0067